Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Operations (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash from Operations for 7 consecutive years, with 83289000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 9.07% to 83289000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 345102000.0 through Dec 2025, up 0.62% year-over-year, with the annual reading at 345102000.0 for FY2025, 0.62% up from the prior year.
  • Cash from Operations for Q4 2025 was 83289000.0 at Beam Therapeutics, down from 81479000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 218490000.0 in Q1 2022, with the low at 109815000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 44264200.0, with a median of 76407500.0 recorded in 2024.
  • Peak annual rise in Cash from Operations hit 666.36% in 2022, while the deepest fall reached 3880.93% in 2022.
  • Over 5 years, Cash from Operations stood at 1830000.0 in 2021, then tumbled by 3880.93% to 69191000.0 in 2022, then surged by 295.22% to 135073000.0 in 2023, then crashed by 156.54% to 76365000.0 in 2024, then decreased by 9.07% to 83289000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 83289000.0, 81479000.0, and 76450000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.